Culbertson A N Co Inc buys $4,239,645 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Culbertson A N Co Inc scooped up 3,125 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 12, 2016. The investment management firm now holds a total of 103,004 shares of Abbott Laboratories which is valued at $4,239,645.Abbott Laboratories makes up approximately 1.52% of Culbertson A N Co Inc’s portfolio.

Other Hedge Funds, Including , Creative Planning boosted its stake in ABT in the latest quarter, The investment management firm added 6,173 additional shares and now holds a total of 212,235 shares of Abbott Laboratories which is valued at $8,735,593. Abbott Laboratories makes up approx 0.06% of Creative Planning’s portfolio. Hilton Capital Management added ABT to its portfolio by purchasing 22,165 company shares during the most recent quarter which is valued at $964,178. Abbott Laboratories makes up approx 0.25% of Hilton Capital Management’s portfolio.Trust Co Of Oklahoma reduced its stake in ABT by selling 5,891 shares or 15.49% in the most recent quarter. The Hedge Fund company now holds 32,144 shares of ABT which is valued at $1,381,228. Abbott Laboratories makes up approx 0.77% of Trust Co Of Oklahoma’s portfolio.Academy Capital Management Inctx reduced its stake in ABT by selling 96 shares or 0.07% in the most recent quarter. The Hedge Fund company now holds 139,395 shares of ABT which is valued at $5,989,803. Abbott Laboratories makes up approx 1.60% of Academy Capital Management Inctx’s portfolio.

Abbott Laboratories closed down -2.34 points or -5.38% at $41.16 with 2,38,96,101 shares getting traded on Tuesday. Post opening the session at $43.2, the shares hit an intraday low of $41.02 and an intraday high of $43.27 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.